BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 17952838)

  • 1. Chromium in metabolic and cardiovascular disease.
    Hummel M; Standl E; Schnell O
    Horm Metab Res; 2007 Oct; 39(10):743-51. PubMed ID: 17952838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromium in the prevention and control of diabetes.
    Anderson RA
    Diabetes Metab; 2000 Feb; 26(1):22-7. PubMed ID: 10705100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A scientific review: the role of chromium in insulin resistance.
    Havel PJ
    Diabetes Educ; 2004; Suppl():2-14. PubMed ID: 15208835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of high-dose chromium.
    Lamson DW; Plaza SM
    Altern Med Rev; 2002 Jun; 7(3):218-35. PubMed ID: 12126463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromium picolinate for insulin resistance in subjects with HIV disease: a pilot study.
    Feiner JJ; McNurlan MA; Ferris RE; Mynarcik DC; Gelato MC
    Diabetes Obes Metab; 2008 Feb; 10(2):151-8. PubMed ID: 18190429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes: response to Martin et al.
    Mark DA
    Diabetes Care; 2006 Dec; 29(12):2764; author reply 2764-5. PubMed ID: 17130232
    [No Abstract]   [Full Text] [Related]  

  • 7. Recent advances in the nutritional biochemistry of trivalent chromium.
    Vincent JB
    Proc Nutr Soc; 2004 Feb; 63(1):41-7. PubMed ID: 15070438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance syndrome and glucose dysregulation in the elderly.
    Mazza AD
    Clin Geriatr Med; 2008 Aug; 24(3):437-54, vi. PubMed ID: 18672181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chromium as an essential element].
    Racek J
    Cas Lek Cesk; 2003; 142(6):335-9. PubMed ID: 12924032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary therapies for diabetes: the case for chromium, magnesium, and antioxidants.
    Guerrero-Romero F; Rodríguez-Morán M
    Arch Med Res; 2005; 36(3):250-7. PubMed ID: 15925015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromium picolinate may favorably influence the vascular risk associated with smoking by combating cortisol-induced insulin resistance.
    McCarty MF
    Med Hypotheses; 2005; 64(6):1220-4. PubMed ID: 15823722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
    Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
    Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of dietary magnesium in cardiovascular disease prevention, insulin sensitivity and diabetes.
    Bo S; Pisu E
    Curr Opin Lipidol; 2008 Feb; 19(1):50-6. PubMed ID: 18196987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome: are we at risk?
    Paudel B
    Nepal Med Coll J; 2007 Sep; 9(3):204-11. PubMed ID: 18092442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight reduction and cardiovascular and metabolic disease prevention: clinical trial update.
    Selwyn AP
    Am J Cardiol; 2007 Dec; 100(12A):33P-37P. PubMed ID: 18154745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutraceutical resources for diabetes prevention--an update.
    McCarty MF
    Med Hypotheses; 2005; 64(1):151-8. PubMed ID: 15533633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic complications of obesity in childhood and adolescence: more than just diabetes.
    Nathan BM; Moran A
    Curr Opin Endocrinol Diabetes Obes; 2008 Feb; 15(1):21-9. PubMed ID: 18185059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of chromium in human metabolism, with special reference to type 2 diabetes.
    Chowdhury S; Pandit K; Roychowdury P; Bhattacharya B
    J Assoc Physicians India; 2003 Jul; 51():701-5. PubMed ID: 14621042
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.
    Vlek AL; van der Graaf Y; Spiering W; Visseren FL;
    J Hum Hypertens; 2008 May; 22(5):358-65. PubMed ID: 18273039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications.
    Fan JG
    J Dig Dis; 2008 May; 9(2):63-7. PubMed ID: 18419637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.